OvaScience (OVAS) Tops Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
OvaScience Reports Third Quarter 2016 Financial Results
November 3, 2016 4:01 PM EDTBroadened Patient Access to AUGMENT with New Clinic Agreements in Canada and Japan
Expanded AUGMENT Clinical Program with Institutional Review Board (IRB) Approval for Company-Sponsored, Multi-Center Trial
Conference Call Today at 4:30 p.m. ET
WALTHAM, Mass.--(BUSINESS WIRE)-- OvaScienceSMÂ (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new female infertility treatments, today reported its third quarter 2016 financial results and highlighted recent accomplishments.
OvaScience is focused on laying the clinical and operational foundation necessary to support the... More
